MK-677: The Oral Growth Hormone Secretagogue
MK-677 (Ibutamoren mesylate) is a non-peptide growth hormone secretagogue that mimics the action of ghrelin at the growth hormone secretagogue receptor (GHSR1a). Developed by Merck Research Laboratories in the 1990s, MK-677 is unique among GH-axis research compounds for its oral bioavailability and long duration of action (Patchett et al., 1995).
Although frequently grouped with research peptides due to its mechanism of action, MK-677 is technically a small molecule peptidomimetic. Its ability to elevate growth hormone and IGF-1 through the ghrelin receptor pathway has generated extensive published research spanning body composition, sleep, bone health, and aging.
Molecular Profile
- Chemical name: 2-amino-2-methyl-N-[1-(1-methylsulfonylspiro[2H-indene-1,4'-piperidine]-6-yl)but-2-enyl]-propanamide methanesulfonate
- Classification: Non-peptide GH secretagogue / ghrelin receptor agonist
- Molecular weight: ~528.7 Da (mesylate salt)
- CAS number: 159752-10-0
- Receptor target: GHSR1a (growth hormone secretagogue receptor type 1a)
- Bioavailability: Orally active
- Half-life: ~24 hours (supports once-daily dosing)
Mechanism of Action
MK-677 activates the GHSR1a receptor, the same receptor bound by the endogenous hormone ghrelin. This activation triggers growth hormone release from anterior pituitary somatotroph cells through a pathway distinct from but synergistic with GHRH (Smith et al., 1997):
- Direct pituitary stimulation: GHSR1a activation on somatotrophs increases intracellular calcium and triggers GH exocytosis
- Hypothalamic amplification: MK-677 also acts on GHSR1a in the hypothalamus, stimulating GHRH release while suppressing somatostatin tone
- Pulsatile amplification: GH is released in amplified pulses rather than continuous elevation, preserving physiological secretion patterns
- IGF-1 elevation: Sustained GH pulse amplification increases hepatic IGF-1 production, which remains elevated with continued administration
Research Area 1: Growth Hormone and IGF-1 Elevation
Chapman et al. (1996) published the seminal clinical study demonstrating that MK-677 at 25 mg/day increased GH secretion and IGF-1 levels in healthy older adults. Mean serum IGF-1 concentrations rose by approximately 60% over baseline, reaching levels comparable to young adults, while maintaining the pulsatile GH release pattern.
Murphy et al. (1998) confirmed sustained effects over 12 months of treatment, with IGF-1 levels remaining elevated throughout the study period without tachyphylaxis (tolerance). The sustained response without desensitization distinguishes MK-677 from some other GH secretagogues.
Research Area 2: Sleep Quality and Architecture
Copinschi et al. (1997) conducted polysomnographic studies demonstrating that MK-677 improved sleep quality in young and elderly subjects. Specifically, MK-677 increased stage IV (deep/slow-wave) sleep duration by 50% and REM sleep by 20% in healthy young men. In elderly subjects, REM sleep duration increased by approximately 20%.
The sleep-promoting effects of MK-677 are consistent with ghrelin's known role in sleep regulation and are particularly relevant given the parallel decline of both GH secretion and sleep quality with aging.
Research Area 3: Bone Mineral Density
Murphy et al. (2001) studied MK-677's effects on bone turnover markers over 18 months in elderly adults. The study demonstrated increased bone formation markers (osteocalcin) and bone mineral density at the femoral neck, suggesting anabolic effects on bone tissue mediated through the GH-IGF-1 axis.
Nass et al. (2008) further confirmed bone density improvements in a 2-year clinical study, with sustained increases in bone mineral density at multiple skeletal sites. The research supports the role of the GH-IGF-1 axis in maintaining bone mass during aging.
Research Area 4: Body Composition
Svensson et al. (1998) investigated MK-677's effects on body composition in obese males and reported increased fat-free mass (lean mass) and a transient increase in basal metabolic rate. The improvements in lean mass were consistent with GH's known protein-anabolic effects.
Nass et al. (2008) observed that MK-677 treatment over two years in healthy elderly subjects produced modest but statistically significant increases in fat-free mass, though fat mass was not significantly reduced. The body composition effects were accompanied by maintained IGF-1 elevation throughout the study.
Research Area 5: Appetite and Metabolic Effects
As a ghrelin receptor agonist, MK-677 stimulates appetite — an effect that distinguishes it from other GH secretagogues. Svensson et al. (1998) documented significant increases in appetite and caloric intake in MK-677-treated subjects. This orexigenic effect is relevant both as a research observation and as a consideration in study design.
MK-677 treatment has also been associated with modest increases in fasting glucose and insulin resistance in some studies, consistent with GH's known diabetogenic effects. Nass et al. (2008) reported increased fasting glucose levels during long-term administration, highlighting the metabolic complexity of sustained GH axis activation.
Current Research Status
MK-677 has been studied in over a dozen published clinical trials involving hundreds of human subjects, giving it one of the most extensive clinical datasets of any GH secretagogue. While it has not received FDA approval for any therapeutic indication, the breadth of published clinical data provides a substantial evidence base for ongoing research into GH axis physiology, aging, and metabolic regulation.
Research Disclaimer
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.